Evidence map›Paper›PMID 24416384›Full record

ArticlePloS one2014

n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Ru-Huei Fu, Horng-Jyh Harn, Shih-Ping Liu, Chang-Shi Chen, Wen-Lin Chang, Yue-Mi Chen, Jing-En Huang, Rong-Jhu Li, Sung-Yu Tsai, Huey-Shan Hung and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Antidepressant-Like Effects ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Studying the mechanisms of neurodegeneration:Frontiers in cellular neuroscience · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Molecules (Basel, Switzerland) · 2021
    Article
  16. International journal of molecular sciences · 2021
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Ru-Huei FuGraduate Institute of Immunology, China Medical University, Taichung, Taiwan ; Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan.
Horng-Jyh HarnDepartment of Pathology, China Medical University Hospital, Taichung, Taiwan.
Shih-Ping LiuCenter for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan ; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Chang-Shi ChenDepartment of Biochemistry and Molecular Biology, National Cheng Kung University, Tainan, Taiwan.
Wen-Lin ChangGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Yue-Mi ChenGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Jing-En HuangGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Rong-Jhu LiGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Sung-Yu TsaiGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.
Huey-Shan HungCenter for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan ; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Woei-Cherng ShyuGraduate Institute of Immunology, China Medical University, Taichung, Taiwan ; Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan.
Shinn-Zong LinGraduate Institute of Immunology, China Medical University, Taichung, Taiwan ; Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan ; Department of Neurosurgery, China Medical University Beigang Hospital, Yunlin, Taiwan ; Department of Neurosurgery, Tainan Municipal An-Nan Hospital-China Medical University, Tainan, Taiwan.
Yu-Chi WangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan.
China Medical University · TWChina Medical University Hospital · TWAn-Nan Hospital · TWIndustrial Technology Research Institute · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is the second most common degenerative disorder of the central nervous system that impairs motor skills and cognitive function. To date, the disease has no effective therapies. The identification of new drugs that provide benefit in arresting the decline seen in PD patients is the focus of much recent study. However, the lengthy time frame for the progression of neurodegeneration in PD increases both the time and cost of examining potential therapeutic compounds in mammalian models. An alternative is to first evaluate the efficacy of compounds in Caenorhabditis elegans models, which reduces examination time from months to days. n-Butylidenephthalide is the naturally-occurring component derived from the chloroform extract of Angelica sinensis. It has been shown to have anti-tumor and anti-inflammatory properties, but no reports have yet described the effects of n-butylidenephthalide on PD. The aim of this study was to assess the potential for n-butylidenephthalide to improve PD in C. elegans models. METHODOLOGY/PRINCIPAL

findingsIn the current study, we employed a pharmacological strain that expresses green fluorescent protein specifically in dopaminergic neurons (BZ555) and a transgenic strain that expresses human α-synuclein in muscle cells (OW13) to investigate the antiparkinsonian activities of n-butylidenephthalide. Our results demonstrate that in PD animal models, n-butylidenephthalide significantly attenuates dopaminergic neuron degeneration induced by 6-hydroxydopamine; reduces α-synuclein accumulation; recovers lipid content, food-sensing behavior, and dopamine levels; and prolongs life-span of 6-hydroxydopamine treatment, thus revealing its potential as a possible antiparkinsonian drug. n-Butylidenephthalide may exert its effects by blocking egl-1 expression to inhibit apoptosis pathways and by raising rpn-6 expression to enhance the activity of proteasomes. CONCLUSIONS/SIGNIFICANCE: n-Butylidenephthalide may be one of the effective neuroprotective agents for PD.

Indexed as

alpha-SynucleinAngelica sinensisAnimalsAntiparkinson AgentsCaenorhabditis elegansCaenorhabditis elegans ProteinsDisease Models, AnimalDopamineDopaminergic NeuronsDrugs, Chinese HerbalGene Expression RegulationHumansLongevityMuscle CellsOxidopamineParkinson Diseasealpha-Synucleinangelicae sinensis extractAntiparkinson AgentsbutylidenephthalideCaenorhabditis elegans ProteinsDopamineDrugs, Chinese HerbalEGL-1 protein, C elegansOxidopaminePhthalic AnhydridesProteasome Endopeptidase ComplexRepressor ProteinsRPN-6.1 protein, C elegans

Identifiers

PMID24416384
PMCPMC3885701
OpenAlexW2026798880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.